Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.34
+0.02 (0.38%)
Jan 21, 2026, 4:00 PM CET
-37.16%
Market Cap325.77M
Revenue (ttm)n/a
Net Income (ttm)-103.70M
Shares Out61.23M
EPS (ttm)-2.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,722
Average Volume50,507
Open5.31
Previous Close5.32
Day's Range5.02 - 5.34
52-Week Range4.18 - 10.98
Beta0.75
RSI42.47
Earnings DateFeb 11, 2026

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 28
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements